Historical Valuation
Nurix Therapeutics Inc (NRIX) is now in the Fair zone, suggesting that its current forward PS ratio of 29.03 is considered Fairly compared with the five-year average of -5.73. The fair price of Nurix Therapeutics Inc (NRIX) is between 18.41 to 30.37 according to relative valuation methord.
Relative Value
Fair Zone
18.41-30.37
Current Price：19.30
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Nurix Therapeutics Inc (NRIX) has a current Price-to-Book (P/B) ratio of 3.73. Compared to its 3-year average P/B ratio of 2.54 , the current P/B ratio is approximately 47.11% higher. Relative to its 5-year average P/B ratio of 2.75, the current P/B ratio is about 35.63% higher. Nurix Therapeutics Inc (NRIX) has a Forward Free Cash Flow (FCF) yield of approximately -13.18%. Compared to its 3-year average FCF yield of -23.45%, the current FCF yield is approximately -43.78% lower. Relative to its 5-year average FCF yield of -19.63% , the current FCF yield is about -32.84% lower.
P/B
Median3y
2.54
Median5y
2.75
FCF Yield
Median3y
-23.45
Median5y
-19.63
Competitors Valuation Multiple
AI Analysis for NRIX
The average P/S ratio for NRIX competitors is 97.54, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX.O) exhibits a P/S ratio of 29.03, which is -70.24% above the industry average. Given its robust revenue growth of -37.29%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NRIX
1Y
3Y
5Y
Market capitalization of NRIX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NRIX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NRIX currently overvalued or undervalued?
Nurix Therapeutics Inc (NRIX) is now in the Fair zone, suggesting that its current forward PS ratio of 29.03 is considered Fairly compared with the five-year average of -5.73. The fair price of Nurix Therapeutics Inc (NRIX) is between 18.41 to 30.37 according to relative valuation methord.
What is Nurix Therapeutics Inc (NRIX) fair value?
NRIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nurix Therapeutics Inc (NRIX) is between 18.41 to 30.37 according to relative valuation methord.
How does NRIX's valuation metrics compare to the industry average?
The average P/S ratio for NRIX's competitors is 97.54, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX) exhibits a P/S ratio of 29.03, which is -70.24% above the industry average. Given its robust revenue growth of -37.29%, this premium appears unsustainable.
What is the current P/B ratio for Nurix Therapeutics Inc (NRIX) as of Jan 10 2026?
As of Jan 10 2026, Nurix Therapeutics Inc (NRIX) has a P/B ratio of 3.73. This indicates that the market values NRIX at 3.73 times its book value.
What is the current FCF Yield for Nurix Therapeutics Inc (NRIX) as of Jan 10 2026?
As of Jan 10 2026, Nurix Therapeutics Inc (NRIX) has a FCF Yield of -13.18%. This means that for every dollar of Nurix Therapeutics Inc’s market capitalization, the company generates -13.18 cents in free cash flow.
What is the current Forward P/E ratio for Nurix Therapeutics Inc (NRIX) as of Jan 10 2026?
As of Jan 10 2026, Nurix Therapeutics Inc (NRIX) has a Forward P/E ratio of -5.19. This means the market is willing to pay $-5.19 for every dollar of Nurix Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nurix Therapeutics Inc (NRIX) as of Jan 10 2026?
As of Jan 10 2026, Nurix Therapeutics Inc (NRIX) has a Forward P/S ratio of 29.03. This means the market is valuing NRIX at $29.03 for every dollar of expected revenue over the next 12 months.